Announced Wed, 8 Jul · 11:00 IST
Routine dematerialisation compliance certificate for Q1 FY27
Compliance View source PDF
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹831.00
prior close
₹831.95
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
—+0.5+0.3+0.3-1.8+0.8-0.1-1.0+2.6-0.7————
Up moveDown movePending
AI summary
Alembic Pharmaceuticals has submitted a routine certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The certificate, issued by its Registrar MUFG Intime India, confirms that shares received for dematerialisation during the quarter were duly processed and confirmed to the depositories, and that the cancelled certificates have been verified and the depositories recorded as the registered owner in the company's records.
Likely market impact
No material impact on shareholders. This is a standard quarterly compliance filing related to share dematerialisation processing.